Navigation Links
Inverseon's Founder and SAB Member Published in PNAS

SAN FRANCISCO, Feb. 19 /PRNewswire/ -- Inverseon, Inc. ( announces the publication in the February 17, 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) entitled, "Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model." The article was edited by Robert Lefkowitz, The James B. Duke Professor of Medicine at Duke University, and there is an accompanying supportive commentary on this essential asthma signaling pathway by Raymond Penn of the University of Maryland School of Medicine.

"This work using knockout mice confirms prior results from Bond and collaborators using inverse agonists, a subset of beta blockers, in mice and patients (Callaerts-Vegh PNAS 2004; Nguyen AJRCMB 2008; Hanania 2008) that a reduction in Beta2-adrenoceptor signaling attenuates the asthma phenotype. The current work extends the prior observations by ruling out the possibility that the effects of inverse agonists are exerted via biased agonism. Together, these are a remarkable set of observations that point the way towards a possible therapeutic strategy based upon the use of drugs that had previously been considered contraindicated in asthma. The precise mechanism by which Beta2-adrenoceptor signaling exacerbates the asthma phenotype is not yet known, but is an active area of study. Fully understanding this phenomenon and exploiting it therapeutically will be of tremendous interest to the asthma community," commented Burton F. Dickey, MD, Professor & Chair, Dept. of Pulmonary Medicine, M.D. Anderson Cancer Center and Inverseon Scientific Advisory Board member.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded by EGB Advisors, LLC of San Francisco based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.


    William J. Garner, MD
    1701 Jackson Street, 102
    San Francisco, CA 94109
    (917) 653-0470

This release was issued through eReleases(TM). For more information, visit

SOURCE Inverseon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute
2. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
3. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
4. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
5. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
6. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives
9. Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology
10. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
11. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Post Your Comments:
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... PUNE, India , December 1, 2015 ... --> adds "Endometriosis - ... that provides an overview on therapeutic pipeline ... capabilities to create effective counter strategies to ... by identifying new targets and MOAs to ...
Breaking Medicine Technology:
(Date:12/1/2015)... HANGZHOU, China (PRWEB) , ... December 01, 2015 , ... ... will result in its largest order to date. , The order will be ... implant systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. ... the patient care experience, and propose exciting enhancements to the medical landscape. , ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... engine optimization companies, announced today that it has officially launched a sleek, mobile-ready ... SEO, explained that his company’s new website clearly outlines the benefits that its ...
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... Trevor ... corporate support as they play for the chance to represent the United States. This ... the opportunity to be a part of their journey in addition to offering corporate ...
(Date:11/30/2015)... ... December 01, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
Breaking Medicine News(10 mins):